Your browser does not support JavaScript! News Archive | Biofidelity

News

Press Releases


Biofidelity and CellCarta today announced a strategic partnership agreement to utilize Aspyre® Lung in global clinical trials.


Biofidelity is proud to have been selected as a grant recipient by the Green Business Impact Programme, a collaborative effort led by Cambridge City Council, South Cambridgeshire District Council, Huntingdonshire District Council, the Cambridgeshire and Peterborough Growth Hub and the Cambridgeshire & Peterborough Combined Authority and administered by Allia Impact, Ltd.


Biofidelity announced the publication of data that highlights how Aspyre® technology addresses the urgent need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer.


View All

Media Coverage


Biofidelity is hoping to improve minimal residual disease (MRD) testing and cancer patient monitoring with the rollout of its Enspyre sample enrichment platform.


Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types with Aspyre Lung.


Biofidelity’s successful $24 million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing Aspyre Lung genomic testing protocol.


View All